Breaking Finance News

Cowen and Company upgraded Achaogen Inc (NASDAQ:AKAO) to Outperform in a statement released earlier today.

Boasting a price of $5.10, Achaogen Inc (NASDAQ:AKAO) traded 3.45% higher on the day. With the last stock price close up 23.30% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Achaogen Inc has recorded a 50-day average of $4.88 and a two hundred day average of $4.14. Volume of trade was down over the average, with 0 shares of AKAO changing hands under the typical 229,016

Cowen and Company has upgraded Achaogen Inc (NASDAQ:AKAO) to Outperform in a statement released on 11/28/2016.

Performance Chart

Achaogen Inc (NASDAQ:AKAO)

With a total market value of $0, Achaogen Inc has with a one year low of $2.59 and a one year high of $6.18 .

A total of 6 brokers have issued a report on the stock. 1 broker rating the stock a strong buy, 3 brokers rating the stock a buy, 2 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell with a consensus target price of $14.17.

General Information About Achaogen Inc (NASDAQ:AKAO)

Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections: a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. Its development plan for plazomicin includes over two Phase III clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.